The pharmacogenetics of imanitib. [Genome Med. 2010] - PubMed result

Genome Med. 2010 Nov 30;2(11):85. [Epub ahead of print]
The pharmacogenetics of imanitib.

Dulucq S, Krajinovic M.

Centre de recherche, CHU Sainte-Justine, Départements de Pédiatrie et Pharmacologie, Université de Montréal, 3175 Côte-Ste-Catherine, Montréal, QC H3T 1C5, Canada. maja.krajinovic@umontreal.ca.

Abstract

ABSTRACT: Imatinib mesylate (IM), a tyrosine kinase inhibitor, is one of the first molecularly targeted therapies to have been used in the clinic. It has proven to be efficient in the treatment of chronic myeloid leukemia and also in other malignancies that involve expression of a tyrosine kinase. However, some patients can develop resistance and others suffer from toxic side effects. The pharmacokinetics of IM depends on several enzymes and transporters, and several studies have attempted to identify genetic factors associated with variable drug levels and clinical responses using a candidate gene approach. Larger and more homogenous studies are still needed to replicate the findings obtained so far, or to analyze other genetic variations to get clearer insights into how IM treatment can be tailored to each patient's genetics. Here we summarize pharmacogenetic studies of IM and highlight the genetic markers that could be used to improve the treatment and management of diseases for which IM is used.

PMID: 21122163 [PubMed - as supplied by publisher]
The pharmacogenetics of imanitib. [Genome Med. 2010] - PubMed result